APPLIED THERAPEUTICS INC (APLT) Stock Price & Overview

NASDAQ:APLTUS03828A1016

Current stock price

0.103 USD
+0 (+0.19%)
At close:
0.1051 USD
+0 (+2.04%)
After Hours:

The current stock price of APLT is 0.103 USD. Today APLT is up by 0.19%. In the past month the price increased by 0.29%. In the past year, price decreased by -83.12%.

APLT Key Statistics

52-Week Range0.09 - 1.5
Current APLT stock price positioned within its 52-week range.
1-Month Range0.09 - 0.114
Current APLT stock price positioned within its 1-month range.
Market Cap
14.863M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.10
Dividend Yield
N/A

APLT Stock Performance

Today
+0.19%
1 Week
+6.96%
1 Month
+0.29%
3 Months
-87.88%
Longer-term
6 Months -75.80%
1 Year -83.12%
2 Years -98.55%
3 Years -89.80%
5 Years -99.53%
10 Years N/A

APLT Stock Chart

APPLIED THERAPEUTICS INC / APLT Daily stock chart

APLT Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to APLT. When comparing the yearly performance of all stocks, APLT is a bad performer in the overall market: 99.26% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

APLT Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to APLT. Both the profitability and financial health of APLT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APLT Earnings

On November 13, 2025 APLT reported an EPS of -0.13 and a revenue of 1.00M. The company beat EPS expectations (8.96% surprise) and beat revenue expectations (194.12% surprise).

Next Earnings DateApr 13, 2026
Last Earnings DateNov 13, 2025
PeriodQ3 / 2025
EPS Reported-$0.13
Revenue Reported1M
EPS Surprise 8.96%
Revenue Surprise 194.12%

APLT Forecast & Estimates

9 analysts have analysed APLT and the average price target is 0.26 USD. This implies a price increase of 147.57% is expected in the next year compared to the current price of 0.103.

For the next year, analysts expect an EPS growth of 32.11% and a revenue growth 80.83% for APLT


Analysts
Analysts48.89
Price Target0.26 (152.43%)
EPS Next Y32.11%
Revenue Next Year80.83%

APLT Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

APLT Financial Highlights

Over the last trailing twelve months APLT reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 93.2% compared to the year before.


Income Statements
Revenue(TTM)1.00M
Net Income(TTM)-18.14M
Industry RankSector Rank
PM (TTM) N/A
ROA -52.77%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%72.92%
Sales Q2Q%719.67%
EPS 1Y (TTM)93.2%
Revenue 1Y (TTM)-90.43%

APLT Ownership

Ownership
Inst Owners60.63%
Shares144.30M
Float136.08M
Ins Owners2.01%
Short Float %N/A
Short RatioN/A

About APLT

Company Profile

APLT logo image Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2019-05-09. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The firm is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).

Company Info

IPO: 2019-05-09

APPLIED THERAPEUTICS INC

545 Fifth Avenue, Suite 1400

New York City NEW YORK 10017 US

CEO: Shoshana Shendelman

Employees: 28

APLT Company Website

APLT Investor Relations

Phone: 12122209226

APPLIED THERAPEUTICS INC / APLT FAQ

Can you describe the business of APPLIED THERAPEUTICS INC?

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2019-05-09. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The firm is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).


What is the current price of APLT stock?

The current stock price of APLT is 0.103 USD. The price increased by 0.19% in the last trading session.


Does APPLIED THERAPEUTICS INC pay dividends?

APLT does not pay a dividend.


How is the ChartMill rating for APPLIED THERAPEUTICS INC?

APLT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the market capitalization of APLT stock?

APPLIED THERAPEUTICS INC (APLT) has a market capitalization of 14.86M USD. This makes APLT a Nano Cap stock.


Can you provide the ownership details for APLT stock?

You can find the ownership structure of APPLIED THERAPEUTICS INC (APLT) on the Ownership tab.